You are here

Semin Arthritis Rheum DOI:10.1016/j.semarthrit.2017.02.003

Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.

Publication TypeJournal Article
Year of Publication2017
AuthorsSparks, JA, Barbhaiya, M, Karlson, EW, Ritter, SY, Raychaudhuri, S, Corrigan, CC, Lu, F, Selhub, J, Chasman, DI, Paynter, NP, Ridker, PM, Solomon, DH
JournalSemin Arthritis Rheum
Volume47
Issue1
Pages133-142
Date Published2017 Aug
ISSN1532-866X
Abstract

BACKGROUND: The role of low dose methotrexate (LDM) in potential serious toxicities remains unclear despite its common use. Prior observational studies investigating LDM toxicity compared LDM to other active drugs. Prior placebo-controlled clinical trials of LDM in inflammatory conditions were not large enough to investigate toxicity. The Cardiovascular Inflammation Reduction Trial (CIRT) is an ongoing NIH-funded, randomized, double-blind, placebo-controlled trial of LDM in the secondary prevention of cardiovascular disease. We describe here the rationale and design of the CIRT-Adverse Events (CIRT-AE) ancillary study which aims to investigate adverse events within CIRT.DESIGN: CIRT will randomize up to 7000 participants with cardiovascular disease and no systemic rheumatic disease to either LDM (target dose: 15-20mg/week) or placebo for an average follow-up period of 3-5 years; subjects in both treatment arms receive folic acid 1mg daily for 6 days each week. The primary endpoints of CIRT include recurrent cardio vascular events, incident diabetes, and all-cause mortality, and the ancillary CIRT-AE study has been designed to adjudicate other clinically important adverse events including hepatic, gastrointestinal, respiratory, hematologic, infectious, mucocutaneous, oncologic, renal, neurologic, and musculoskeletal outcomes. Methotrexate polyglutamate levels and genome-wide single nucleotide polymorphisms will be examined for association with adverse events.SUMMARY: CIRT-AE will comprehensively evaluate potential LDM toxicities among subjects with cardiovascular disease within the context of a large, ongoing, double-blind, placebo-controlled trial. This information may lead to a personalized approach to monitoring LDM in clinical practice.

DOI10.1016/j.semarthrit.2017.02.003
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/28284844?dopt=Abstract

Alternate JournalSemin. Arthritis Rheum.
PubMed ID28284844